News / 10.01.2019

ALAMEDA, Calif.--(BUSINESS WIRE)--Jan. 10, 2019-- LifeMap Sciences, Inc., a subsidiary of AgeX Therapeutics, Inc. (NYSE American: AGE) announced today that Tianjin Novogene Medical Laboratory, LifeMap, and Shanghai Shanyi today announced a partnership to provide a combined, best-of-breed Clinical NGS analysis and interpretation platform for Tianjin Novogene Medical Laboratory’s customers in China....

News / 09.01.2019

ALAMEDA, Calif. – January 9, 2019 – AgeX Therapeutics, Inc. (NYSE American: AGE)  announced today the publication of data relating to its cell therapy product candidate AgeX-BAT1 for Type II diabetes and obesity in the peer-reviewed scientific journal Stem Cell Research & Therapy. Scientists now realize that the activity of brown adipose tissue (BAT), also known as “brown” or “good” fat, is markedly lost with age. This loss may contribute to metabolic disturbances seen in Type II diabetes and obesity as well as a heightened cardiovascular risk. AgeX-BAT1 is comprised of regenerative cells capable of becoming BAT and is intended to return BAT levels back to those found in young adults. AgeX is targeting Type II diabetes and obesity as they are areas of high unmet medical need and present multi-billion-dollar market opportunities....

News / 29.11.2018

ALAMEDA, Calif. – November 29, 2018 AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerative Medicine conference 2018 in Valencia, Spain on Monday December 3, 2018.
News / 17.09.2018

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors intends to set a new record date for the distribution of AgeX Therapeutics, Inc. (“AgeX”) shares to BioTime shareholders. The ratio of one share of AgeX common stock for every 10 shares of BioTime common stock will remain unchanged. A new date provides time to complete necessary administrative activities and receive all regulatory approvals.
News / 16.08.2018

ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), focused on the development and commercialization of novel therapeutics targeting human aging, today announced that it has acquired certain patents and patent applications from Escape Therapeutics relating primarily to the use of the HLA-G gene to suppress rejection of transplanted cells and tissues. The Company plans to utilize the technology in conjunction with its pluripotent stem cell platform for applications in regenerative medicine.
News / 02.08.2018

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced a new strategic alignment between AgeX Therapeutics and Juvenescence Limited, a global leader in developing therapeutics focused on improving and extending human lifespans.
News / 11.07.2018

ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will present at the conference Ending Age-Related Diseases: Investment Prospects & Advances in Research, Thursday, July 12 at Cooper Union in New York City.